Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 유대현 | - |
| dc.date.accessioned | 2021-08-03T05:26:55Z | - |
| dc.date.available | 2021-08-03T05:26:55Z | - |
| dc.date.issued | 2016-11-14 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/34338 | - |
| dc.title | Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks | - |
| dc.type | Conference | - |
| dc.citation.conferenceName | ACR 2016 | - |
| dc.citation.conferencePlace | Washington DC | - |
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 2. Conference Papers
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.